Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 197

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 197
---
 drop the subject from the trial, increase the needed enrollment size for the clinical trial or extend its duration; |

| • |     | subjects may choose an alternative treatment for the indication for which Kineta is developing its product candidates, or participate in competing clinical trials; |

| • |     | subjects may experience severe or unexpected drug-related adverse effects; |

| • |     | clinical trials of Kineta’s product candidates may produce unfavorable, inconclusive or clinically insignificant results; |

| • |     | Kineta may decide to, or regulators or IRBs or ECs may require Kineta to, make changes to a clinical trial protocol or conduct additional preclinical studies or clinical trials, or Kineta may decide to abandon product development programs; |

| • |     | Kineta may need to add new or additional clinical trial sites; |

| • |     | Kineta’s third-party contractors, including those manufacturing its product candidates or conducting clinical trials on its behalf, may fail to comply with regulatory requirements or meet their contractual obligations to Kineta in a timely manner, or at all; |

| • |     | Kineta may experience manufacturing delays, and any changes to manufacturing processes or third-party contractors that may be necessary or desired could result in other delays; |

| • |     | Kineta may experience import delays of its product candidates manufactured abroad; |

| • |     | Kineta or its third-party contractors may experience delays due to complications associated with pandemics or other health crises; |

| • |     | the cost of preclinical testing and studies and clinical trials of any product candidates may be greater than Kineta anticipates or greater than Kineta’s available financial resources; |

| • |     | the supply or quality of Kineta’s product candidates or other materials necessary to conduct clinical trials of its product candidates may be insufficient or inadequate or Kineta may not be able to obtain sufficient quantities of combination therapies for use in clinical trials; |

| • |     | reports may arise from preclinical or clinical testing of other cancer therapies that raise safety or efficacy concerns about Kineta’s product candidates; and |

| • |     | regulators may revise the requirements for approving Kineta’s product candidates, or such requirements may not be as Kineta anticipates. |

If Kineta is required to conduct additional clinical trials or other testing of its product candidates beyond the clinical trials and testing that Kineta contemplates, if Kineta is unable to successfully complete clinical trials or 115

other testing of its product candidates, if the results of